We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Alnylam Pharmaceuticals and Dicerna Pharmaceuticals have formed a development and commercialization collaboration on investigational RNAi therapeutics.
Alnylam Pharmaceuticals has partnered with Dicerna Pharmaceuticals to develop and commercialise ribonucleic acid interference (RNAi) therapies to treat alpha-1 antitrypsin (A1AT) deficiency-associated liver disease.